study_id,year,design,effect_type,effect_point,ci_low,ci_high,n_treat,n_ctrl,risk_of_bias,doi,journal_id,intervention,control,outcome,duration_weeks,population
bitter-orange_2019_1,2019,RCT,MD,-2.335,-2.828,-1.843,118,36,some,10.3996/j.jacc.2019.2865,jacc,Bitter Orange supplement,Placebo,Proteinuria,12,Athletes
bitter-orange_2017_2,2017,cohort,MD,-1.216,-1.635,-0.798,108,46,low,10.3611/j.j_sleep_res.2017.2699,j_sleep_res,Bitter Orange supplement,Control group,Proteinuria,16,Athletes
bitter-orange_2022_3,2022,RCT,MD,-2.092,-2.487,-1.697,28,112,high,10.8914/j.neuropsychopharmacol.2022.8997,neuropsychopharmacol,Bitter Orange supplement,Placebo,eGFR (mL/min/1.73m²),12,Athletes
bitter-orange_2015_4,2015,RCT,MD,0.031,-0.396,0.459,111,92,some,10.4669/j.low_quality_journal.2015.6542,low_quality_journal,Bitter Orange supplement,Placebo,eGFR (mL/min/1.73m²),12,Patients with CKD
